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ABSTRACT
We describe a method for the simultaneous high performance liquid
chromatographic determination of several antiarrhythmic drugs and some
of their metabolites after extraction from 2.5 ml of spiked pooled sera.
The extracts were applied to a C8 reversed phase column. Nine compounds
of interest were resolved within the 30 minute run. An initial mobile
phase of 80% phosphate (25 mmol/L, pH 3.5), 20 % organic (acetonitrile:
methanol, 2:3) was maintained for 2 min at which time a linear gradient
was used to change the mobile phase to 30% phosphate, 70% organic at
20 min after injection. This composition was maintained for an addi
tional 5 min. Absorbance at 212 nm was used for detection. Peak area
ratios of drug to internal standard (N-propionylprocainamide) were used
for quantitation. The relative standard deviations (and mean solute
concentrations) of daily duplicate determinations for 15 days are:
procainamide (PA), 5.1% (5.9 mg/L); N-acetylprocainamide (NAPA), 9.3%
(6.0 mg/L); mono-N-deal kyldisopyramide (NDAD), 3.7% (4.1 mg/L); diso
pyramide (DIS0P), 4.3% (4.0 mg/L); quinidine (QUIN), 4.5% (6.5 mg/L);
propranolol (PR0PL), 5.1% (97 yg/L); and dihydroquinidine (DIHYQ), 9.3%
(0.69 mg/L). A propranolol metabolite, 4-hydroxypropranolol (4-OHP),
was resolved but not quantitated.
INTRODUCTION
Quinidine, procainamide, disopyramide, and propranolol are drugs
that are prescribed for their cardiac antiarrhythmic qualities. The
determination of the blood serum concentration of each drug may be use
ful to the physician in an effort to improve the effectivenes of ther
apy.
Quinidine is a myocardial depressant (as are procainamide and di
sopyramide) that may cause serious side effects at serum concentrations
that are only ten percent higher than the therapeutic range. These
include life threatening arrhythmias, serious hypotension, and hyper
sensitivity reactions (1).
Procainamide usage in certain patients, characterized as "slow
acetylators", may produce a potentially fatal syndrome similar to Lupus
Erythematosus. This condition has been related to the rate of conver
sion of procainamide to its pharmacologically active, acetylated meta
bolite, N-acetyl procainamide. Nausea and weakness may occur at pro
cainamide serum levels fifteen percent higher than the therapeutic range.
Serum concentrations of N-acetyl procainamide are not known when these
toxic symptoms appear (1).
Disopyramide may cause worsening arrhythmia and electrocardiogram
changes with high doses and increased serum concentrations. Mono-N-
dealkyl disopyramide is a major metabolite whose pharmacoactivity is
still undetermined (1).
Propranolol is a 3-adrenergic blocking agent which affects the
cardiac action of the catecholamines. There is poor correlation of
drug dosage with blood concentration that is believed to be due to
large variations in the rate of metabolism (1). Serum levels are usu
ally requested to ensure that a minimum therapeutic concentration has
been achieved and/or if the patient is in compliance with therapy.
Side effects at high levels may rarely include congestive heart failure
and pulmonary edema. One of the fifteen identified metabolites, 4-
hydroxypropranolol , is believed to possess antiarrhythmic activity (2).
Our objectives in developing a high performance liquid chromato
graphic method for the quantitation of procainamide, N-acetyl procainamide,
disopyramide, mono-N-dealkyldisopyramide. quinidine, and propranolol
were threefold. First, we sought to develop an assay for these drugs
that would be free from major interferences that are present in the
fluorometric methods for quinidine (3) and propranolol (4) and the
colorimetric method for procainamide (5). Secondly, we wanted a means
of detecting and quantitating serum levels of the major drug metabolites,
whether or not they are reported to have pharmacologic activity, to
aid in drug dosage regimens. Lastly, we needed a method that could be
used for the simultaneous determination of as many of the antiarrhythmic
drugs and metabolites as possible. In this way, we could best utilize
a microprocessor controlled liquid chromatograph with an autosampling
system that could run unattended and perform an analysis on an extracted
specimen regardless of which drug or combination of drugs was present
in the sample.
Miller and Tacker have reviewed previous HPLC methods for multi-
component serum analysis (6). To our knowledge, this is the first
report of a method that can be used for the simultaneous measurement
of several antiarrhythmic drugs and metabolites in serum.
EXPERIMENTAL
APPARATUS
A Hewlett-Packard Model 1084B high performance liquid chromato
graph was used in this study. It is a microprocessor controlled system
in which keyboard entries are used to control several parameters;
including a linear, variable by time, elution gradient; mobile phase
flow rate; column temperature; and detector wavelength selection. The
microprocessor also integrates peak areas by continuously monitoring
the slope of the chromatogram. The sample injector is a variable
volume syringe that can be operator adjusted to deliver 10 to 200 yL.
An automatic sampling system allows up to 60 samples to be run without
further operator intervention. The variable wavelength detector is a
single cell, dual wavelength type with an operating range of 190 nm to
600 nm.
An Altex Ultrasphere Octyl C8 (25 cm x 4.6 mm i.d.) column (Rainen
Instrument Co., Woburn, MA 01801) was used for the separations. A
Brownlee RP8 guard column (Rainen Instrument Co., Woburn, MA 01801)
was used to prolong the analytical column lifetime.
Clin-Elute CE-1003 columns (Analytichem International, Inc., Lawn-
dale, CA 90260) were used to extract the drugs and internal standard
from serum.
Silica Gel 60 (0.2 mm thickness) pre-coated thin layer chromto-
graphy sheets (EM Reagents, American Scientific Products, McGaw Park,
IL 60085) were used as the TLC stationary phase.
REAGENTS
All aqueous solutions were prepared with deionized water that had
been passed through a 0.22 y filter. Acetonitrile and methanol were
HPLC grade (Fisher Scientific Co., Pittsburgh, PA) and used without
further purification. Reagent grade H3P04, NaH2P04'H20, concentrated
NH40H, and ethyl acetate (Fisher Scientific Co.) were used as received.
The drugs, metabolites, and internal standard, used to prepare
stock methanol solutions, were not purified further. Quinine, N-acetyl
procainamide (both from Sigma Chemical Co., St. Louis, M0 63178),
and N-propionyl procainamide (Pierce Chemical Co., Rockford, IL) were
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purchased. The following were gifts supplied by the respective manu
facturers: procainamide- HC1 (E.R. Squibb & Sons, Princeton, NJ 08540);
disopyramide phosphate and mono-N-dealkyl disopyramide (G.D. Searle and
Co., Chicage, IL 60680); propranolol *HC1 and 4-hydroxypropranolol
(Ayerst Laboratories, Inc., New York, NY); quinidine-S04 (Eli Lilly
and Co., Indianapolis, IN 46206); and dihydroquinidine (A.H. Robbins,
Co., Richmond, VA 23220).
Stock solutions were prepared in calibrated conical centrifuge
tubes by dissolving each substance in an appropriate amount of HPLC
grade methanol (approximately 5 mL) to obtain a concentration of 1.0
g of free drug/L.
Working methanol stock solutions were prepared for N-propionyl-
procainamide and propranolol of 0.2 g/L, respectively, by appropriate
dilution of the concentrated stocks. To preserve the integrity of the
4-hydroxypropranolol, which is unstable for long periods in methanol,
60 yL of stock solution was transferred to several test tubes, the
methanol evaporated under N2 at 50 C, and the residue was stored stop
pered at room temperature (60 yg per tube).
PROCEDURE
The aliquots of frozen pooled sera (standards, control, and blank
are thawed at room temperature and vortexed for 10s to ensure homogen-
iety.
Pipet 200 yL of 0.1 mol/L HC1 into labeled 16 x 150 mm glass col
lection tubes that are then positioned below a corresponding Clin-Elute
column. The pH of the column is adjusted by adding 200 yL of 1 mol/L
Na?C0^. This is followed by the addition of internal standard, 50 yL
of N-propionyl procainamide (0.2 g/L in methanol). Pipette 2.5 mL of
serum onto the column and wait 3 min for equilibration. Three additions
of 4 mL each of the extraction solvent (methylene chloride:hexane:isoamyl
alcohol, 49:49:2, v:v) follow. Wait for the dripping to stop before
adding the next portion. Vortex the collection tubes for 45s and cen
trifuge at 2000 rpm for 10 min. Aspirate and discard the organic su
pernatant. Add 300 yL of methanol to the remaining aqueous phase in
the collection tube, vortex for 5s, and evaporate to dryness at
50 C
under a gentle stream of N2 Dissolve the residue in 150 yL of the
initial mobile phase (described below) and inject 75 yL into the liquid
chromatograph.
CHROMATOGRAPHIC CONDITIONS
The mobile phase was in two reservoirs: one contained 25 mmol/L
phosphate, pH 3.5, and the other, a mixture of acetonitrile and methanol
(2:3). The phosphate was prepared by mixing 25 mmol/L solutions of
H3P04 and NaH2P04 until a pH of 3.5 was achieved. This aqueous solution
was then passed through a 1.2 y Millipore filter under vacuum which
also effectively de-gassed the solution. The organic mixture was de
gassed by heat and vacuum in the chromatograph reservoir.
The elution was performed at 30 C with a flow rate of 1.0 mL/min.
The initial mobile phase composition was 80% phosphate and 20% organic.
At 2 min after the injection of sample, a linear gradient was started
that reached 30% aqueous and 70% organic after 20 min into the run.
This mixture was maintained for another 5 min when the run was termin
ated. The mobile phase was returned to its initial composition and
allowed to equilibrate with the column for 5 min before another sample
was chromatographed. Total run time was therefore 30 min.
The variable wavelength detector, with a 12 yL, 10 mm flow cell,
was set at 212 nm for sample monitoring. The reference wavelength was
430 nm. A Chromatogram of all assay components is presented in Figure 1.
LINEARITY
The linearity of detector response, as a function of the concentra
tion of each component of interest, was confirmed by comparison of the
peak areas of two-fold serially diluted mixtures in mobile phase. Table
1 lists the range of each substance for which the area did not deviate
more than 10% from the expected dilution factor. The serum concentra
tions that would correspond to the measured linearity range by use of
our extraction procedure, assuming 100% recovery, are also shown. The
accepted therapeutic ranges are included for comparative purposes.
The 4-hydroxypropranolol proved to be unstable in methanol (i.e.
stock solutions) and in mobile phase. The stability of a fresh solution
was sufficient to determine the chromatographic retention time, but
it was not adequate for quantification. This propranolol metabolite
is reported to have amphoteric extraction characteristics (7), and
a serum concentration of 5-40 yg/L (8). It was concluded from this
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Fig. 1. Chromatogram of antiarrhythmic drugs, metabolites, and internal
standard. The components (1.5 yg each) are identified by their respec
tive retention times, are: A, procainamide (5.68 min); B, N-acetylpro-
cainamide (7.64 min); C, N-propionyl procainamide (10.88 min); D, mono-
N-dealkyldisopyramide (14.90 min); E, 4-hydroxypropranolol (15.94 min);
F, disopyramide (17.51 min); G, quinidine (18.51 min); H, dihydroquinidine
(19.79 min); and I, propranolol (21.49 min).
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TABLE 1. DETECTOR LINEARITY AT 212 nm.
Substance
Amount
Injected (yq)
0.27 - 17.5
Equivalent Serum
Concentration3
(mq/L)
Therapeutic Serum
Concentration0
(ma/L)
Procainamide 0.22 - 14.0 4 - 8
NAPA 0.14 - 17.5 0.11 - 14.0 4 - 8
NPP 0.14 - 17.5 b -
NDAD 0.03 - 17.5 0.03 - 14.0 ?
Disopyramide 0.07 - 17.5 0.05 - 14.0 2 - 4
Quinidine 0.14 - 17.5 0.11 - 14.0 3 - 6
Propranolol 0.005 - 0.33 3 -
210d
20 - 100d
a
b
c
d
Assumes 100 percent recovery in reported extraction procedure (see
Table 3 for actual recoveries).
Internal standard.
From reference (1).
Concentration yg/L.
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information that 4-hydroxypropranolol was an inappropriate compound to
include in this assay.
Linearity of the overall assay procedure was determined through
the use of calibration curves. These were prepared from spiked sera
with the use of N-propionyl procainamide as the internal standard. The
peak area ratio of drug /internal standard (ordinate) was plotted against
the concentration of drug in the serum spike (abscissa). The high
standard is approximately twice the high therapeutic serum concentration
in each case. Serial dilutions of the high standard to concentrations
of 1/3 and 1/9, using the same serum pool but without drug or metabolite
as the diluent, were prepared to cover the full range of clinical in
terest. Standard curves for all drugs and metabolites are shown in
Figures 2-8. Linear regression analysis data of the standard curves
are summarized in Table 2. The small values for the Y-intercept indi
cates that no endogenous interferences are present. This was confirmed
by extraction and elution of blank sera.
Absolute recovery was studied by the comparison of peak areas from
stock solution residues, that had been reconsituted in mobile phase,
with the peak areas from extracts of a spiked serum pool. Extraction
efficiencies for several serum concentrations of each drug are summar
ized in Table 3. The internal standard (N-propionyl procainamide) had
an absolute recovery of 82% (SD t 4% n=12) when 50 yL of a 0.2 g/L
methanol solution was added to the Clin-Elute column as described in
the procedure. Although the absolute recoveries of N-acetyl procainamide
and propranolol are less than 100%, they are also independent of con
centration and therefore should be adequate for clinical use.
PRECISION
The reproducability of the injection system of the chromatograph
was determined by injecting pure drug standards (n=10). The variation
in retention times for any analyte was always less than 0.1 min. The
relative standard deviation of each chromatographic peak area was less
than 4% for all of the drugs except for the 4-hydroxypropranolol. When
peak area of each drug was divided by the area of the internal standard,
relative standard deviations improved to less than 1%.
Precision studies of drug quantification were conducted with two
pools of spiked sera, one for within-run variation and one for run-to-
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Fig. 7. Dihydroquinidine calibration curve from spiked serum extracts.
Comparison of peak area drug/peak area internal standard with drug con
centration in mg/L. Each point represents an average of three determin
ations. Standards are: 1.2 mg/L, 0.4 mg/L, and 0.13 mg/L.
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TABLE 2. LINEAR REGRESSION ANALYSIS OF 3 POINT CALIBRATION CURVES
FROM SPIKED SERA3
f
Correlation
Slope Y-intercept Coefficient
0.2195 -0.0027 0.9990
0.1344 -0.0055 0.9991
0.1531 0.0024 0.9994
0.1470 -0.0012 0.9994
0.3426 0.0513 0.9986
0.5435 0.0008 0.9938
0.3364 -0.0057 0.9998
Procainamide
N-acetyl procainamide
Mono-N-deal kyldisopyramidec
Disopyramide0
Quinidine
Propranolol
Dihydroquinidinee
Ordinate: Peak area drug or metabolite/Peak area internal standard.
Abscissa: Concentration of drug of metabolite standards as indicated
below.
Standards: 1.3, 4.0, and 12 mg/L.
Standards: 0.9, 2.7, and 8.0 mg/L.
Standards: 22, 67, and 200 yg/L.
e Standards: 0.13, 0.4, and 1.2 mg/L.
raw data used in calculation.f
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TABLE 3. ABSOLUTE EXTRACTION EFFICIENCIES FROM SPIKED SERA AT VARIOUS
DRUG CONCENTRATIONS
CONCENTRATION: (mg/L) 16
Procainamide
N-acetyl procainamide
Mono-N-dealkyldisopyr amide
Disopyramide
Quinidine
98% 98% 96% 99% 85%
74 74 73 72 63
99 102 102 108 98
103 104 103 114 104
100 103 102 112 103
CONCENTRATION: (mq/L) 1.4 0.70 0.35 0.18 0.09
Dihydroquinidine 98% 96% 97 107% 97%
CONCENTRATION: (yq/L) 250 125 63 31
Propranolol 73% 70% 76% 72%
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run variation. Spiked serum for the run- to-run variation study was
stored frozen in 3 mL aliquots. The spiked serum was analyzed fifteen
times for within-run variation. The run-to-run assays were performed
in duplicate, for fifteen days over a four week period.
The relative standard deviation for all drugs, in both precision
studies, is less than 10% (Tables 4,5, and 6). Data in Table 7 indi
cates the variation in retention times over the four week period of
the run-to-run precision study. By using the shifts in the internal
standard retention time to correct for shifts in the time of elution
of the assayed drugs, the reproducability was within 0.1 min over
the four week period. This is particularly significant because the
microprocessor can then be easily programmed to identify peaks of in
terest by the relative retention times of analyte to that of any selec
ted standard (9). Chromatograms of spiked sera are presented in Fig. 9.
INTERFERENCES
Several types of interferences were investigated in the study.
Frequently used prescription drugs, over-the-counter drugs, and car
diac associated drugs were tested as potential exogenous interfering
agents. Lipemic, icteric, and hemolyzed sera were tested for possible
endogenous interferences. Heparin and EDTA were investigated as suit
able anticoagulants. Dihydroquinidine, a contaminant of quinidine,
was identified by thin layer chromatography and quantified by liquid
chromatography.
Drug Interference
The drugs listed in Table 8 were tested for interference with the
assay drugs. The drugs were dissolved in mobile phase and dispensed
singly into 1.5 mL injection vials, at their respective high therapeutic
serum concentrations. The concentration in the vial was made to approx
imate the concentration that would result from a hypothetical serum
sample that was carried through the extraction procedure. 75 yL of
solution from each vial was injected into the chromatograph. The
resulting retention times were compared to the internal standard and
antiarrhythmic drug retention times. Previous experience with the ef
ficiency of the column indicated that drugs eluting within 0.5 min of
any component to be assayed might interfere with the accurate quanti
fication of that component. Table 9 lists the drugs that were tested
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TABLE 4. WITHIN-RUN PRECISION DRUG CONCENTRATION mg/L (PROPRANOLOL yg/L)
PA NAPA NDAD DISOP. QUIN. DIHYQ. PROPL.
7.3 7.3 3.6 3.3 6.1 0.59 134
7.0 7.1 3.4 3.1 5.8 0.54 124
7.1 6.4 3.7 3.6 6.6 0.64 144
6.5 6.1 3.3 3.1 5.8 0.58 121
7.1 7.3 3.5 3.2 5.9 0.57 131
6.6 5.5 3.6 3.5 6.6 0.64 140
7.2 7.4 3.6 3.3 6.0 0.59 134
6.7 6.1 3.5 3.3 6.2 0.61 132
7.0 6.5 3.5 3.2 5.9 0.59 129
6.8 6.6 3.4 3.1 5.9 0.54 124
6.9 6.8 3.4 3.2 5.9 0.57 125
7.1 6.8 3.5 3.2 6.1 0.58 131
7.0 6.8 3.5 3.2 5.9 0.58 128
7.2 7.4 3.5 3.2 6.0 0.55 127
7.0 6.5 3.5 3.2 6.0 0.55 129
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TABLE 5. RUN-TO-RUN PRECISION (AVERAGE OF DUPLICATES)
DRUG CONCENTRATION mg/L (PROPRANOLOL yg/L)
a Peak area not integrated properly.
DATE PA
5.8
NAPA
5.4
NDAD
3.9
DISOP.
3.9
QUIN.
6.4
DIHYQ.
0.60
PROPL.
8/15 94
8/19 6.1 6.1 4.0 3.8 6.3 0.59 92
8/20 6.4 6.7 4.0 3.9 6.4 0.60 98
8/22 6.0 6.0 4.0 3.9 6.5 0.60 96
8/24 6.2 6.6 4.2 4.0 6.6 0.73 98
8/26 6.0 6.2 4.2 4.2 7.0 0.76 101
8/27 5.5 5.3 3.8 3.7 6.2 1.19 97
9/4 6.0 5.9 4.2 4.1 6.8 0.75 94
9/7 5.7 5.4 4.1 4.2 6.7 0.71 106
9/8 6.3 6.6 4.3 4.2 6.7 0.72 91
9/9 6.0 6.3 4.1 4.0 6.4 0.71 103
9/10 6.1 6.1 4.2 4.1 6.6 0.77 107
9/11 5.2 4.7 3.8 3.7 5.8 0.69 95
9/12 5.9 5.9 4.0 3.9 6.2 0.69
9/19 5.9 6.2 4.1 4.1 6.4 0.71 94
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TABLE 6. REPRODUCIBILITY FOR ANTIARRHYTHMIC DRUG DETERMANATIONS AND
REPRESENTATION PEAK AREA RATIOS
Within-Run Serum
(n=15)
Pool
Mean
(mg/L)
7.0
Standard
Deviation
(mg/L)
0.23
Relative
Standard
Deviation
(%)
Procainamide 3.4
N-acetyl procainamide 6.7 0.56 8.3
Mono-N-deal kyl disopyramide 3.5 0.10 2.7
Disypyramide 3.3 0.14 4.2
Quinidine 6.1 0.23 3.9
Propranolol 130a 6.1a 4.7
Dihydroquinidine 0.58 0.031 5.3
Concentration yg/L.
Procainamide
N-acetyl procainamide
Mono-N-deal kyl d i sopyrami de
Disopyramide
Quinidine
Propranolol
Dihydroquinidine
Run-to-Run Serum
Poo'
(n=15)a
1
Mean
(mg/L)
Standard
Deviation
(mg/L)
Relative
Standard
Deviation
(%)
Peak Area
Ratio, Drug
Internal
Standard
5.9 0.30 5.1 1.22
6.0 0.55 9.3 0.75
4.1 0.15 3.7 0.59
4.0 0.17 4.3 0.57
6.5 0.29 4.5 2.18
98b 5.0b 5.1 0.054
0.69 0.064 9.3 0.20
a Between assay variation was determined by assaying the pool in dup
licate on 15 days over a four week period.
Concentration yg/L.
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TABLE 7. RETENTION TIMES RUN-TO-RUN PRECISION STUDY
VALUES OBTAINED OVER A 4 WEEK PERIOD
Rt RANGE (MIN) R RANGE (MIN) CORRECTED
Procainamide 5.25-5.53 5.32-5.50
NAPA 7.11 - 7.59 7.32 - 7.49
NPP 10.47. - 10.85
NDAD 14.52 - 14.84 14.68 - 14.78
Disopyramide 17.03 - 17.37 17.18 - 17.31
Quinidine 18.04 - 18.54 18.28 - 18.44
Dihydroquinidine 19.61 - 20.10 19.85 - 20.01
Propranolol 21.30 - 21.82 21.53 - 21.71
a
Corrected for shifts in internal standard retention within the run.
a
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Fig. 9. Chromatograms for serum extracts of (a) blank serum, (b) spiked
with drug at comparable detector sensitivity, and (c) serum spiked with
drug at reduced sensitivity to illustrate peak shapes and relative
heights. The concentrations are equal to those listed in Table 5 for
run-to-run precision. The components are: A, procainamide; B, N-
acetyl procainamide; C, N-propionyl procainamide; D, mono-N-dealkyldiso-
pyramide; F, disopyramide; G, quinidine; H, dihydroquinidine; and I,
propranolol .
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TABLE 8. DRUGS TESTED FOR INTERFERENCE AT THE SERUM LEVELS INDICATED
Anticonvulsants Cardiac associated drugs
Phenytoin 20 mg/L Methyl Dopa 4.0 mg/L
Phenobarbital 60 mg/L Hydralazine 1.0 mg/L
Primadone 15 mg/L Chlorthiazide 2.0 mg/L
Carbamazepine 10 mg/L Bretylium tosylate 1.0 mg/L
Valproic acid 100 mg/L Isosorbide dinitrate 4.0 mg/L
Metaprolol 4.0 mg/L
Analgesics Furosemide 10 mg/L*
Salicylate 400 mg/L Hydrochlorthiazide 4.0 mg/L
Meperidine 0.5 mg/L Lidocaine 5.0 mg/L
Acetaminophen 40 mg/L
Pentazocine 0.3 mg/L Miscellaneous
Propoxyphene 0.5 mg/L Theophylline 20 mg/L
Quinine 5.0 mg/L
Sedative / Hypnotics
Flurazepam 1.0 mg/L * No data available on serum le
Glutethimide 4.0 mg/L Level
calculated on
dose.
recommend'
Methaqualone 5.0 mg/L
Meprobamate 20 mg/L
Psychotherapeuti cs
Diazepam 2.0 mg/L
Chlordiazepoxide 10 mg/L
Oxazepam 1.0 mg/L
Amitriptylene 0.5 mg/L
Imipramine 0.5 mg/L
Doxepin 0.5 mg/L
Chlorpromazine 1.0 mg/L
Prochlorperazine 1.0 mg/L
Thioridizine 1.0 mg/L
Therapeutic concentrations found in References 1,10, and 11.
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cTABLE 9. INTERFERANCE STUDY: DRUG RETENTION TIME AND PEAK AREA
Pim Rta Peak Areab
Amitriptylene _ mrCNIT
NR
NR
NR
NR
Imipramine
Propoxyphene
Chlorpromazine
Thioridizine
Prochloroperazine 3.2 335,400
Methyl Dopa. 3.3 733,200
Hydralazine* 5.0 7:20,000
(Procainamide) 5.3 1,938,000
Theophylline* 6.0 10,660,000
Acetaminophen 6.3 7,036,000
Bretylium Tosylate* 6.9 149,100
(NAPA) 7.3 1,515,000
Chlorthiazide* 7.3 116,000
Hydrochlorthiazide 8.1 1,921,000
(NPP) 10.6 1,514,000
Salicylate 12.4 10,000,000
Bretylium Tosylate 12.7 219,600
Primadone 14.0 3,162,000
Lidocaine* 14.5 2,920,000
Meprobamate* 14.6 43,030
(NDAD) 14.7 309,300
Metaprolol 16.0 648,000
(Disoypramide) 17.2 956,000
Phenobarbital* 17.3 5,510,000
Furosemide* 18.0 1,583,000
Meperidine* 18.2 88,100
(Quinidine) 18.3 2,680,000
Quinine* 18.4 2,401,000
Pentazocine* 19.5 79,420
Valproic Acid* 19.7 174,000
(Dihydroquinidine) 19.9 196,900
Isosorbide Dinitrate* 19.9 833,600
P-Chlorodisopyramide 20.6 Internal std.
Carbamazepine* 20.9 4,440,000
Phenytoin* 21.0 2,799,000
Glutethimide* 21.3 1,767,000
Diazepam* 21.4 223,900
(Propranolol) 21.5 56,240
Flurazepam 22.4 538,900
Methaqualone 22.4 3,071,000
Oxazepam 22.7 626,300
Chlordiazepoxide 22.9 2,719,000
Doxepin 22.9 354,400
a r -retention time in min. Area calculated by integrator at 212 nm,
NR-no response (no detectable elution under assay conditions).
* Compound may interfere with an assay component because of its
elution characteristics.
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and their respective retention times. Those components identified
with an asterik fulfill the criterion as possible interfering agents.
Separate aliquots of pooled drug free sera were individually
spiked with the possible interfering drugs at the concentrations indic
ated in Table 8. Each was taken through the extraction procedure and
injected into the chromatograph. Drug peak areas before and after ex
traction were compared to assess the extraction characteristics of each
of the drugs.
To determine if consumption of quinine water (tonic water) would
increase quinidine levels, a volunteer drank 830 mL (28 oz) of Schwepp's
tonic water in a 15 min period. Blood was drawn 120 min later for de
termination of quinidine by our assay procedure.
A review of the drug extraction data from Table 10 shows the fol
lowing; an apparent increase in procainamide concentration of 0.2 mg/L
by hydralazine and an apparent increase in dihydroquinidine concentra
tion of 0.06 mg/L by pentazocine, both of which are not clinically sig
nificant. Tonic water consumption would falsely increase quinidine by
0.1 mg/L, also insignificant. Quinine, a stereoisomer of quinidine,
significantly interferes with the assay of quinidine. A 5.0 mg/L
quinine level would increase quinidine by 5.0 mg/L. Lidocaine, a car
dioactive drug with basic properties, will interfere with the quan
tification of NDAD.
The interference of glutethimide and carbamazepine, neutral ex
tracting drugs, with propranolol, was investigated further. Three se
parate pooled drug free serum aliquots were spiked with either carba-
mazepine (10 mg/L), glutethimide (4.0 mg/L), or propranolol (100 yg/L).
An aliquot of each of these sera was processed using the normal assay
protocol. A second aliquot of each of the spiked sera was processed
through to the aspiration of the organic eluting solvent. Instead of
evaporating the HC1 phase immediatedly after solvent aspiration, 8 mL
of additional solvent was added to the tubes that contained 200 yL of
HC1. The tubes were then vortexed and centrifuged again. The organic
solvent was aspirated and then the HC1 phase was evaporated to dryness.
A third aliquot of spiked sera was taked through two additional solvent
addition/aspiration steps. After the first 8 mL of new extraction sol
vent had been aspirated, another 8 mL was added. These tubes were then
vortexed, spun, aspirated, and dried. During the aspiration step,
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TABLE 10. EXTRACTION DATA ON COMPOUNDS WHICH MAY INTERFERE BECAUSE
OF THEIR CLOSE ELUTION TO AN ASSAY DRUG
Druq
Serum cone.
(mq/L)
Peak Area
Pre-extract
Peak Area
Post-extract % Recovery
Chlorthiazide 2.0 119,200 1,100 0.9
Meperidine 0.5 521,900 NRa 0
Phenytoin 20 3,040,000 NR 0
Furosemide 10 3,610,000 NR 0
Meprobamate 20 40,200 NR 0
Diazepam 2.0 251,500 NR 0
Valproic acid 100 160,000 NR 0
Bretylium 1.0 120,600 NR 0
Isosorbide
di nitrate
1.0 178,000 MR 0
Theophylline 20 12,835,000 NR 0
Phenobarbital 60 6,830,000 NR 0
Hydralazine 1.0 660,000 193,950 29.4
Lidocaine 5.0 2,739,000 2,503,000 91.4
Quinine 5.0 3,195,000 3,286,990 102.9
Carbamazepine 10 4,706,000 555,700 11.8
Glutethimide 4.0 1,944,000 193,060 9.9
Pentazocine 0.3 72,640 36,050 49.6
Tonic water _ - 400,800 -
a
NR-no response, no detectable elution under assay conditions.
b
Area calculated by integrator at 212 nm.
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approximately 7.5 mL of the 8 ml of organic solvent can be removed
without disturbing the 200 yL HC1 layer. In this way the initial ex
traction and back extraction steps remove 94% of neutral extracting
compounds. A second solvent addition step increases the removal of
these interfering drugs to 99.6%. A third addition would theoretically
remove 99.98% of all neutral extracting compounds. The results of
this experiment are tabulated in Table 11.
Both carbamazepine and glutethimide can be eliminated by the extra
extraction steps. However, with each successive step there is a 30%
loss of propranolol. After the third extraction, a 100 yg/L serum
propranolol has a peak area of 25,000. This could present a detection
problem with intermediate propranolol levels. There is no apparent
loss of internal standard in these extraction steps. The 82% recovery
of internal standard is therefore probably due to a loss of 18% in the
column. A propranolol serum standard should therefore be taken through
the multiple extraction steps along with the patient's specimen to com
pensate for extraction losses.
Endogenous Interference
Lipemic, icteric, and hemolyzed sera were tested for possible in
terferences with the assay drugs. Four pools were prepared of normal,
lipemic, icteric, and hemolyzed sera. Aliquots of each were spiked with
the assay drugs at concentrations to represent both high and low ther
apeutic serum levels: High Low
Quinidine (mg/L) 5 2
Procainamide (mg/L)
NAPA (mg/L)
Disopyramide (mg/L)
NDAD (mg/L)
Propranolol (yg/L)
DIHYQ (mg/L)
Each specimen was then extracted in duplicate.
were also run as controls.
All sera, regardless of whether or not a potential endogenous in
terference was present, had elution peaks at 4.57, 9.02, and 19.27 min.
These substances, do not coelute with any of the assay drugs. Lipemic
sera also had an endogenous peak at 12.34 min, area 175,000, that did
not interfere with the assay. Another peak, that eluted 0.17 min after
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5 2
5 2
4 2
2 0.5
100 30
0.6 0.2
Equivalent serum blanks
TABLE 11. DATA ON THE ADDITIONAL EXTRACTION STEPS WHICH ARE REQUIRED
TO REMOVE THE INTERFERING DRUGS CARBAMAZEPINE AND
GLUTETHIMIDE FROM THE PROPRANOLOL ASSAY.
Extractions
Pre-extraction
Extraction Protocol
One Added Extraction
Two Added Extractions
Apparent Propranolol Level (yg/L)
Carbamazepine9 Glutethimide9 Propranolol'
5129 2693 135
733 178 99
39 0 73
0 0 45
Individual serum aliquots were spiked at the following concentrations;
carbamazepine (10 mg/L), glutethimide (4 mg/L), and propranolol
(100 yg/L).
Drug standards were prepared in mobile phase at the indicated con
centrations and chromatographed without extraction.
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NDAD, produced the following areas in extractions of drug free sera:
hemolyzed (22,100), lipemic (222,400), icteric (52,700). The extract
of normal serum did not have this peak. A NDAD serum level of 0.5 mg/L
produces a peak area of 170,000. Lipemic and icteric sera would sig
nificantly increase NDAD concentrations (Table 12) and should therefore
not be used for analysis of this metabolite of disopyramide. Results
of spiked sera (Table 12) show an elevation of NDAD levels in both li
pemic and icteric specimens. Other results, such as the apparent de
crease in propranolol in the low therapeutic spike of hemolyzed serum,
could not be explained on the basis of the drug free serum data. Ic
teric sera also show an apparent procainamide increase. No explanation
is offered for these data. Because of the problems related to the use
of lipemic, icteric, and hemolyzed sera, they should not be accepted
as appropriate samples for analysis of the antiarrhythmic drugs.
EDTA plasma and heparinized plasma were tested for suitability
in assaying the antiarrhythmic drugs. Seventy ml of whole blood,
one heparinized tube and one tube containing EDTA were drawn from a
volunteer. Approximately sixty ml of the whole blood sample was quickly
added to five ml of normal saline that had been spiked with drugs.
The blood was mixed and transferred to tubes that contained either EDTA,
heparin, or no anticoagulant. All serum and plasma samples were removed
from the cells within one hour. The concentrations of spiked drugs
were approximately as follows: quinidine 5 mg/L, procainamide 5 mg/L,
NAPA 5 mg/L, disopyramide 4 mg/L, NDAD 1 mg/L, dihydroquinidine 0.4
mg/L, and propranolol 100 yg/L. Each of the three specimen types was
extracted in duplicate. Blanks of each specimen type were also analyzed
to determine if any anticoagulant related interferences are present.
No interfering peaks were seen upon extraction of the blank serum or
either of the plasma. It appears from the data in Table 13 that EDTA
plasma, heparinized plasma, or serum may be used for all drugs except
NAPA. EDTA plasma increases NAPA values and should not be used for
assay of the procainamide metabolite. The reason for this increase
could not be explained on the basis of the results of the drug free
extracts. No explantion is offered for this increase.
Dihydroquinidine was identified as a contaminant of the quinidine
sulphate preparation in two ways. First, the retention times of a known
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TABLE 12. ENDOGENOUS INTERFERENCESa,b
SERUM TYPE PA NAPA
Normal 1.87 1.74
Hemolyzed 2.15 2.49
Icteric 2.29 2.06
Lipemic 2.00 1.71
LOW CONCENTRATION
NDAD DISOP. QUIN. DIHYQ. PROPL.
0.59 2.55 2.84 0.26 33.9
0.64 2.33 2.49 0.22 22.6
0.74 2.62 2.92 0.23 30.6
1.38 2.60 3.15 0.25 29.5
HIGH CONCENTRATION
SERUM TYPE PA
4.91
NAPA
4.55
NDAD
2.47
DISOP.
4.89
QUIN.
6.82
DIHYQ.
0.65
PROPL.
Normal 130
Hemolyzed 4.87 5.43 2.39 4.44 6.09 0.56 105
Icteric 5.54 4.89 2.88 5.49 7.65 0.68 124
Lipemic 5.04 5.12 3.16 4.57 6.69 0.60 104
Apparent drug concentration (mg/L), propranolol (yg/L)
Average value of duplicate samples.
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TABLE 13. SERUM VS PLASMA SUITABILITYa'b
PA NAPA NDAD DISOP QUIN DIHYQ PROPL
EDTA 5.00 7.84 0.99 5.37 5.51 0.49 72.5
Heparin 4.80 7.04 0.98 5.59 5.44 0.48 70.2
Serum 4.79 7.01 0.98 5.33 5.50 0.48 74.5
a Apparent drug concentration (mg/L), propranolol (yg/L).
Average value of duplicate analyses.
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solution of dihydroquinidine and the contaminant peak matched exactly.
Secondly, 20 yg each of quinidine (and the contaminant), dihydroquini
dine, and quinine (a stereoisomer of quinidine) were spotted separately
on two silica plates for thin layer chromatography. The Rf's of the
contaminant and dihydroquinidine, with two different mobile phase com
positions, agreed within experimental error (Table 14). All substances
were detected by both short wavelength UV fluorescence and iodoplatinate
spray.
CORRELATION
Procainamide, NAPA, quinidine, and disopyramide were assayed in
patient's sera by our liquid chromatographic method and compared to
commercially available enzymeimmunologic techniques (EMIT) (13).
Sera for determination of procainamide, NAPA, and quinidine were
collected and stored frozen at C until the. time of assay when each
specimen was thawed and vortexed for 5 s to insure homogeneity. Pooled
drug free sera was spiked with disopyramide at various concentrations.
Each sample was assayed once by our liquid chromatographic method and
in duplicate by enzymeimmunoassay. Results by enzymeimmunoassay that
exceeded the method linearity for quinidine and disopyramide (both 8.0
mg/L), or for procainamide and NAPA (both 16.0 mg/L), were diluted
with drug free serum and reassayed. Dihydroquinidine was added to
drug free serum at concentrations of 0.5 mg/L and 1.0 mg/L and assayed
in triplicate by EMIT. Dihydroquinidine is stated in the Syva brochure
to increase a quinidine value of 2.0 mg/L by 30% when present at a
concentration of 0.6 mg/L (i.e. both quinidine and dihydroquinidine
are equally effective antigens in the technique).
Quinidine Correlation
Assay of dihydroquinidine spiked sera by EMIT gave the following
results:
Dihydroquinidine Added Quinidine Found
1.0 mg/L 1-0 mg/L (average)
0.5 mg/L 0.5 mg/L (average)
Dihydroquinidine exhibits 100% cross-reactivity with the EMIT assay
antibody for quinidine. Because of this cross-reactivity and the
ability of the liquid chromatographic method to resolve the two drugs,
the correlation was performed using quinidine (HPLC) vs quinidine
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TABLE 14. THIN LAYER CHROMATOGRAPHY OF QUINIDINE (AND CONTAMINANT),
DIHYDROQUINIDINE, AND QUININE
fb
Mobile
Phase3
Quinidine (Contaminant) Dihydroquinidine Quinine
68:8:4 0.50 (0.44) 0.43 0.41
68:8:8 0 .57 (0.51) 0.52 0.49
a
b
Volume of ethyl acetate:methanol :NH.0H (cone).
Compared to mobile phase migration of 13.5 cm. Detection by short
wavelength UV fluorescence after H2S04:abs. ethanol (90:10) spray
and also by iodoplatinate spray (Reference 12).
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(EMIT), and quinidine plus dihydroquinidine (HPLC) vs quinidine (EMIT).
The correlation data are found in Table 15 and Figure 10. The correla
tion is only slightly affected by the inclusion of dihydroquinidine in
the calculations. Least square regression analysis of the two sets of
data:
Quinidine + Dihydroquinidine (HPLC) vs Quinidine (EMIT)
r = .9508 HPLC = 1.11 (EMIT) - 0.13 n = 25
Quinidine (HPLC) vs Quinidine (EMIT)
r - .9554 HPLC = 1.08 (EMIT) - 0.14 n = 26
This is probably due to the low levels of dihydroquinidine in serum. The
liquid chromatographic assay for quinidine correlates well with enzyme
immunoassay technique. The correlation coefficient, slope, and Y-inter-
cept are all acceptable for clinical use. At present, there is insuf
ficient data on the clinical significance of dihydroquinidine (14,15).
We are reporting quinidine values and keeping records of both compounds
for possible future use.
Procainamide / NAPA
The correlation between HPLC and EMIT for procainamide and NAPA,
as well as the least square regression analysis of the data, are found
in Figures 11 and 12, and Table 16. The ratio of NAPA to procainamide
may reflect the metabolism of procainamide. In patients on chronic
procainamide therapy, high ratios indicate fast acetylation while,
low ratios indicate slow acetylation. Acetylation is genetically
determined (1). Very high ratios also may indicate renal insuf
ficiency due to the accumulation of NAPA. NAPA has a half life of
6 hours compared to 3 hours for procainamide (1).
Disopyramide / NDAD
Because of the infrequent use of disopyramide compared to the
other antiarrhythmics, patient specimens were difficult to obtain.
The method correlation was therefore performed on pooled drug free
sera which had been spiked with disopyramide at several concentrations.
The correlation between HPLC and EMIT for disopyramide, as well as the
least square regression analysis of the data are found in Figure 13 and
Table 17. There is no readily available comparative method for the
analysis of NDAD. Quantification of NDAD may prove valuable because of
its reported high cholergenic potency (16). Reported serum levels of
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TABLE 15. COMPARISON OF HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH
ENZYMEIMMUNOASSAY FOR THE DETERMINATION OF QUINIDINE
EMIT
(mq/L)a
HPLC (mq/L)b
Quin + Dihyq .
%
Total0Specimen Dihyq Quin Dihyq
2643 2.5 2.8 2.6 .16 5.8
6643 0.6 0.6 0.6 .01 2.0
8394 3.3 3.3 3.3 .05 1.5
3243 3.4 3.1 3.0 .07 2.3
2449 3.1 3.5 3.3 .20 5.7
8793 2.5 2.2 2.2 .03 1.3
6527 0.4 0.3 0.3 .02 6.3
3252 1.5 1.4 1.4 .04 2.8
2885 2.9 3.4 3.3 .14 4.1
5454 2.2 2.1 2.0 .09 4.3
4251 3.2 3.7 3.6 .10 2.7
105 1.7 0.7 0.7 .04 1.7
2976 4.0 4.5 4.4 .10 2.6
1607 5.0 5.5 5.3 .18 3.3
3042 2.8 3.1 2.9 .21 6.7
2251 2.4 2.5 2.3 .22 8.7
4622 2.1 2.0 1.9 .05 2.6
3753 2.3 2.0 2.0 c -
2843 1.9 2.1 2.0 .08 3.8
4439 2.5 2.6 2.5 .06 2.3
3986 1.8 2.7 2.7 .04 1.5
2710 1.4 1.4 1.3 .12 8.5
9264 1.2 1.5 1.4 .08 5.4
4010 0.9 1.1 1.0 .07 6.5
5438 3.2 3.3 3.2 .08 2.4
4220 2.6 3.2 3.1 .09 2.8
Average of duplicate assays. EMIT crossreacts 100% with dihydroquin
idine (see text). EMIT result is therefore a sum of quinidine and
dihydroquinidine.
HPLC is capable of quantitating both quinidine and dihydroquinidine.
Dihydroquinidine levels shown to illustrate its low concentration
in patient serum.
Peak area not integrated properly, therefore not included in the correlation
Dihyq % Total =(Dihyq/ (Dihyq + Quin)) x 100.
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1.0 2.0 3.0 4.0
QUINIDINE mg/L EMIT METHOD
5.0 6.0
Fig. 10. Comparison of the high performance liquid chromatograph method
for quinidine (Y-axis) with enzymeimmunoassay (X-axis).
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TABLE 16. COMPARISON OF HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
WITH ENZYMEIMMUNOASSAY FOR DETERMENATION OF PROCAINAMIDE
AND N-ACETYLPROCAINAMIDE
Procainamide (mg/L) NAPA (mg/L)
b NAPA &
Sample #
EMIT3
HPLC EMITa HPLC NAPA/ PA Total
A-l 14.5 15.8 d d - d
A-2 13.6 14.5 16.5 15.3 1.1 29.8
A-3 4.7 4.7 6.7 6.8 l.-\ 11.5
A-4 1.3 1.3 1.8 1.8 1.4 3.1
A-5 2.9 2.3 3.5 2.9 1.3 5.2
A-6 7.1 6.2 d d - d
A-7 1.0 0.9 3.9 3.8 4.2 4.7
A-8 2.5 2.5 2.5 2.3 0.9 4.8
A-9 2.5 2.3 5.4 3.9 1.7 6.2
B-l 6.0 4.4 d d - d
B-2 2.8 2.5 5.0 3.8 1.5 6.3
B-3 4.2 3.8 3.8 2.9 0.8 6.7
B-4 1.3 1.0 1.8 1.2 1.2 2.2
B-5 5.8 5.7 6.7 5.8 1.0 11.5
B-6 3.8 4.0 2.6 2.4 0.6 6.4
B-7 5.9 5.8 6.4 6.1 1.1 H.9
B-8 6.3 5.6 5.0 3.9 0.7 9.5
B-9 1.6 1.2 1.3 0.8 0.7
2.0
C-l 0.5 0.5 1.0 0.8 1.6
1.3
C-2 2.8 2.5 2.3 1.5 0.6
4.0
C-3 5.3 5.0 5.5 3.5 0.7
8.5
C-4 8.3 8.3 d d
- d
C_5 10.3 12.5 10.4 11.0
0.9 23.5
C-6 3.4 3,6 2.5 1.7
0.5 5.3
C-7 14.0 14.7 6.4 5.4
0.4 20.1
C-8 4.3 3.8 5.0 4.1
1.1 7.9
C-9 6.2 6.6 8.9 8.1
1.2 14.7
a Averaae of duplicate assays. ,
*> UsefSl for determining the rate of acety ation
(see Reference 1)
c For o t mum patient management
procainamide as well as the sum of
procainamide and NAPA, should be reported (see Reference 1 .
d Values exceeded the tested method linearity,
not included in the correlation
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2.0 4.0 6.0 8.0 10.0 12.0
PROCAINAMIDE mg/L EMIT METHOD
14.0 16.0
Fig. 11. Comparison of the high perfromance liquid chromatographic method
for procainamide (Y-axis) with enzymeimmunoassay (X-axis).
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2.0 4.o 6.0 8.0 10.0 12.0
N-ACETYLPROCAINAMIDE mg/L EMIT METHOD
14.0 16.0
Fig. 12. Comparison of the high perfromance liquid chromatographic method for
N-acetyl procainamide (Y-axis) with enzymeimmunoassay (X-axis).
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TABLE 17. COMPARISON OF HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH
ENZYMEIMMUNOASSAY FOR THE DETERMINATION OF DISOPYRAMIDE
Specimen9
EMITb
HPLC
A-l 0.5 0.6
A- 2 1.0 1.0
A- 3 1.6 1.5
A-4 2.2 2.3
A- 5 2.1 2.3
A-6 2.7 2.9
A- 7 2.6 2.2
A-8 3.3 3.2
A- 9 3.8 3.3
B-l 4.0 3.6
B-2 4.4 4.2
B-3 4.5 4.5
B-4 5.9 4.7
B-5 4.8 4.5
B-6 5.8 5.3
B-7 5.8 6.5
B-8 6.8 7.5
B-9 6.7 6.1
C-l 7.7 7.9
C-2 8.6C 10.6
C-3 9.7C 9.8
C-4 10. 4C 11.5
C-5 13. 0C 13.1
a
Drug free serum was spiked with disopyramide at various concentrations.
Average of duplicate assays.
Values originally exceeded method linearity.
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2.0 4.0 6.0 8.0 10.0 12.0
DISOPYRAMIDE mg/L EMIT METHOD
14.0 16.0
Fig
for
13. Comparison of the high performance liquid chromatographic method
disopyramide (Y-axis) with enzymeimmunoassay (X-axis).
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NDAD are within the linearity range of our assay, but the exact antiar
rhythmic activity of this metabolite is uncertain (1,17). We are cur
rently reporting disopyramide concentrations and measuring NDAD levels
for possible future use.
Propranolol
At present, insufficient numbers of patient samples prevent us from
acquiring correlation data for propranolol. The liquid chromatographic
method for analysis of propranolol will be compared to our fluorometric
method (4).
TIME COST STUDY
The time required to process individual runs of 4 specimens and 20
specimens was determined (Table 18). The total cost involved in the
analysis of one specimen, when three specimens and one control are
assayed, was also determined. These data are presented in Table 19.
There is a substantial savings in technologist time with the liquid
chromatographic procedure compared to the methods formerly used. Assay
of four specimens for propranolol by fluorometry requires 2.0 hours of
technologist time (4). To assay the same number of patient sera for
procainamide by spectrophotometry, 1.5 hours of technologist time is
required (5). The total cost, however, is higher with liquid chromato
graphic analysis than with the manual methods. This is due primarily
to instrument overhead. Enzymeimmunoassay, which is a precise and
specific technique, is also an expensive method for analysis of these
drugs.
The total cost of performing an EMIT assay for either quinidine,
procainamide, NAPA, or disopyramide is $5.60 for a run of 4 patients
(based on methodology applied to the Abbott ABA-100) (13). Liquid
chromatography is therefore less expensive than EMIT when more than
one drug is requested for assay on a patient's serum.
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TABLE 18. TIME REQUIRED TO PROCESS THE NUMBER OF SPECIMENS INDICATED
THROUGH THE ENTIRE ASSAY PROCEDURE
Process 4 Specimens
Techa Stepb
Step Time Time Total
1. Setup. Assemble all -Mil) (min) (min)
materials, dispense buffer, 12 12 12
serum, and solvent twice.
2. Add third solvent, allow 1
columns to drain.
3. Vortex tubes (back-
extraction).
4. Spin, aspirate solvent.
5. Evaporate, add mobile
phase, and transfer to
injection vial .
6. Run on chromatograph
7. Calculate and report
results.
2
4
5
12
2
7
2
15
20
120
2
19
21
36
56
176
178
Process 20 Specimens
Techa Stepb
Time Time Total
(min) (min) (min)
35 35 35
17
12 12
15 30
20 30
52
64
94
124
12 600 724
10 10 734
Totals: 38 min 3 hr 111 min 12.2 hr
Represents time required for technologist to perform task.
Represents time to complete task.
Represents time from beginning of procedure.
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TABLE 19. TOTAL COST INVOLVED IN THE ANALYSIS OF ONE SPECIMEN WHEN
THREE SPECIMENS AND ONE CONTROL ARE ASSAYED.
Cost Summation9 Amount
Technologist time
Detector lamp use
Analytical column use
Elution solvent
Extraction solvent
Clin-Elute column
Disposables
Instrument
Total $9.66
Includes the cost of assaying the control serum .
Includes wages and benefits.
(Lamp cost / Life time in hr) x hr / run.
Column cost / number of injections.
e
Paper, vial caps, etc.
f Based on 10 year depreciation and service contract cost.
$1.74 a $11.00/hr)
$0.75c
$0.55d
$0.18
$0.08
$0.80
$0.40e
$5.16f
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METHOD DEVELOPMENT
The development of the HPLC antiarrhythmic drug assay consisted of
initially investigating the chromatographic conditions that would affect
drug elution from the analytical column. The instrument parameters were
then studied in an attempt to optimize the assay for maximum sensitivity.
The chosen system was then used for quantitation of the assay components.
Several organic solvents and procedures were also tested for their
ability to extract the antiarrhythmic drugs from spiked serum.
MOBILE PHASE DEVELOPMENT
Most of the experimental work involved in this study was directly
related to the development and optimization of the mobile phase. The
mobile phase conditions that were sought would separate and elute all
components of interest in a reasonable length of time. Several par
ameters were investigated: Composition (percentages of methanol, aceto
nitrile, phosphate), pH, and phosphate concentration. Both isocratic and
gradient systems were used to elute the drugs. Flow rate and column
temperature were also investigated.
Working solutions of drug standards were prepared in a similar
manner for all experiments. Methanol stock solutions of each drug were
grouped into three vials. Drugs with similar retentions were put in
separate groups to help prevent misidentification. Concentrations of
30 - 50 mg/L for each component were used to approach full scale recorder
deflection at a setting of 0.768 absorbance units. full scale (AUFS). The
solvent composition of the vial always corresponded to the starting com
position of the mobile phase being evaluated. In each of the experiments
one of the following chromatographic conditions was varied while the
others were held constant at the indicated values: flowrate 1.0 ml/ min.,
temperature ambient, phosphate buffer 25 mmol/L pH 3.5.
Mobile Phase Composition
The percentage composition of the organic component of the mobile
phase was varied. The percent methanol :acetonitrile was changed from
100:0 to 0:100 in several steps. The ratios of methanol :acetonitrile
that were used were 100:0, 80:20, 70:30, 65:35, 60:40, 55:45, 50:50,
40:60, 30:70, 20:80, and 0:100.
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LU
OC
0:100 20:80 40:60 60:40
RATIO METHANOL : ACETONITRILE
100:0
Fig. 14. Effect of the methanol,' acetonitrile ratio of the mobile phase on
drug retention. Drugs were eluted using gradient analysis in which the
ratio of organic (methanol.acetonitrile)/phosphate changed from 20:80
at 2.0 min to 70:30 at 20 min. Components are: A, procainamide;
B, NAPA; C, NPP; D, lidoc; E, NDAD; F, 4-0H prop!; G, disop; H, quin;
T H-ihv/n- anrl .1 '""'"Opl
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As shown in Figure 14 the retention times of all assay drugs increase
directly with methanol concentration and, conversely, they decrease with
increasing acetonitrile concentration. The change in retention time is var
iable from drug to drug, and results in changes in the elution order of
some components. At methanol concentrations of 0 - 40% quinidine is not
completely resolved from disopyramide. At 100% methanol, dihydroquinidine
is not completely resolved from propranolol. For most assay drugs
resolution improves as methanol concentration is increased from 40% - 80%.
The early peaks broaden and tail severely with high methanol con
centrations ( 80 - 100%). The baseline shows an upward drift with time
due to an increase in the absorbance that results from an increase in
the gradient methanol concentration. At 100% methanol, the increase in
base line absorbance represents a 20% full scale deflection at the end
of the run (instrument attenuation set at 0.768 AUFS). Runs with ace
tonitrile concentrations greater than 60% have significantly smaller
baseline increases. The baseline differences, although noticeable, are
not analytically significant because they occur gradually, and thus do
not affect the instrument's ability to properly integrate all of the
peaks. The slight baseline increase occurring late in the run is due
to increasing methanol in the mobile phase which is a function of the
gradient design (see Experimental section, Chromatographic Conditions).
Figures 15, 16, and 17 illustrate differences in the elution and baseline
of six assay components at 100% methanol, at 100% acetonitrile, and at
60/40 methanol/acetonitrile, which was the ratio adopted for the assay.
This ratio was chosen because all drugs were well resolved.
Phsophate Buffer pH
The effect of the buffer pH on the chromatographic elution of each
drug was studied. Analyses were performed at pHs of 3.5, 4.5, 5.5, and
6.5.
In general, an increase in pH increases drug retention time
(Figure 18). This is expected because all drugs in the study have
basic properties:
Lidocaine pK = 7.85 Quinidine pK = 4.0,8.6
Disopyramide pK = 8.34 Procainamide pK = 9.2
Propranolol = 9.45
(The pKs of NAPA, NDAD, and dihydroquinidine were not available.)
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IN. STRPT
8. 74
1 1.92
J 15.40
s
17. 93 i
%ft-.3ft
21
:E t-p 1080 B
24.9"
Fig. 15. Chromatogram of several assay components which were separated
using a mobile phase organic ratio of 100% methanol: 0% acetonitrile.
The components with their respective retention times (min) are: pro
cainamide (6.07); NAPA (8.74); NPP (11.92); lidoc (15.40); disop (17.99);
and dihyq (21.21).
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I H J ;.thrt
~3 : i-B
3 4:fi
IB. 39
D 11
iWAc 14.
14.
? il . 68
\ 234.
Fig. 16. Chromatogram of several assay components which were separated
using a mobile phase organic ratio of 0% methanol: 100% acetonitrile.
The components with their respective retention times (min) are: procain
amide (4.71); NAPA (4.91); NPP (7.20); lidoc (11.19); disop (14.27);
and dihyq (14.89).
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In.i
STfiF'
5. 34
7 . 04
IB.
c
Z3 14.34
~^\%:*rt
=> 17.18
-*fc- 1 9.71
S4-
Fig. 17. Chromatogram of several assay components which were separated
using a mobile phase organic ratio of 60% methanol: 40% acetonitrile,
(assay protocol conditions). The components with their respective re
tention times (min) are: procainamide (5.34); NAPA (7.40); NPP (10.56);
lidoc (14.34); disop (17.18); and dihyq (19.71).
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3.5 4.5 5.5 6.5
PHOSPHATE BUFFER pH
Fig. 18. Effect of phosphate buffer pH on drug retention. Components
are: A, procainamide; B, NAPA; C, NPP; D, NDAD; E, 4-OH propl ; F,
disop; G, propl; H, quin; I, lidoc; and J, dihyq.
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At low pH these drugs are in an ionized, hydrophilic form and they
would be expected to elute quickly from the nonpolar, hydrophobic
stationary phase. At high pH they are unionized and, hence, are
retarded on the column. The large increase in the retention time of
lidocaine is probably a result of the drug's relatively low pK and it's
subsequent decrease in ionization at pHs 5.5 and 6.5. At the selected
pH for the assay (3.5), all drugs, except NDAD and lidocaine, are sep
arated by at least one min. As the pH increases, propranolol converges
on dihydroquinidine. Further pH increases result in the propranolol
converging on quinidine. Only at pH 6.5 are they again well separated.
At pH 6.5, lidocaine is well resolved from NDAD. If lidocaine were to
be included in the assay, this would be the appropriate pH.
Phosphate Concentration
The concentration of the phosphate buffer was varied over the
concentration range of 12.5 mmol/L to 100 mmol/L. The optimum amount
of phosphate would be the lowest concentration which would allow good
resolution in a reasonable time, and still maintain an adequate buf
fering capacity. High phosphate concentrations may precipitate in the
capillary lines of the liquid chromatograph (internal diameter of 0.0001
inch).
A slight increase in retention time for each of the drugs, is seen
as the concentration is decreased from 100 to 25 mmol/L (Figure 19).
A further decrease in concentration to 12.5 mmol/L results in a dramatic
increase in drug retention. This effect could be due to a loss of buf
fering capacity at such low phosphate concentration. Elution from the
nonpolar column is dependent upon the ability of the buffer to stabilize
the charge on these basic drugs. If this ability is lost, the nonpolar
drugs remain on the hydrophobic column. A phosphate concentration of
25 mmol/L was selected for the assay protocol. Drug elution times were
acceptable and stable from run to run. Phosphate precipitation should
not be a problem at this concentration.
Flowrate
The mobile phase flowrate was varied from 0.5 to 2.0 ml /min in
several steps to determine the affect on the elution of all the assay
components. The drugs were chromatographed at the following flowrates:
2.0, 1.75, 1.5, 1.25, 1.0, 0.75, and 0.5 ml/min.
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LU
PHOSPHATE CONCENTRATION mmol/L
Fiq 19 Effect of phosphate buffer
concentration on drug retention.
Components are: A, procainamide; B, NAPA; C, NPP; D, lidoc; E, NDAD;
F, 4-OH propl; G, disop; H, quin; I, dihyq; and J, propl.
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As theory predicts (18), an increase in the flowrate shortened
the elution time (Figure 20). Elution order was maintained throughout
the range of the flowrate tested. Drug resolution, however, as defined
in Figure 21, decreased directly with flowrate. A comparison of pro
cainamide with disopyramide showed the following:
Flowrate (ml /min) Resolution
2.0 4.90
1.0 3.53
0.5 2.82
An improvement in resolution at higher flowrates is illustrated by NDAD
and lidocaine. These drugs coelute at a flowrate of 0.5 ml /min, but
they separate at 2.0 ml/min. Peak areas were inversely proportional to
flowrate. In all cases, an increase in the flowrate by a factor of two,
decreased the peak area by approximately one-half. Noninterfering,
endogenous peaks from serum components followed the same pattern. This
behavior was thought to be related to the residence time of the absorbing
material in the detector flowcell.
1.0 ml/min was selected as the flowrate for the assay protocol.
Run length was acceptable and the column head pressure of 3000 psi
was within the tolerance of the column. Although drug resolution is
better at 2.0 ml/min than at 1.0 ml/min, a 5400 psi column head pressure
is generated at the higher flowrate. At a given flowrate, head pressure
varies 15% depending on the condition of the filters in the flow system,
the degree of deterioration of the pre-column, and the analytical col
umn. At a flow of 2.0 ml/min, head pressure could exceed the maximum
allowable system pressure of 6000 psi (9). This would result in system
shutdown and possible column damage.
Column Temperature
Drugs were chromatographed at ambient, 35 , 45 , and 55 C to deter
mine the affect of temperature on the analysis. Flowrates of 1.0 and
0.5 ml/min were used at each temperature to determine if elution could
be improved by the use of a high column temperature along with a low
mobile phase flowrate.
At both flowrates, retention times were little affected by temper
ature between ambient and
35
C. (Ambient temperature on the day of
assay was
22 C) (Figures 22 and 23). Because room temperature fluctu
ates between
20
and 30 C, the variation in elution times between
20
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20. Effect of mobile phase flowrate on drug elution.
2.0
Fig.
Components are: A, procainamide; B, NAPA; C, NPP; D, lidoc;
E, NDAD; F, 4-OH propl; G, disop; H, quin; I, dihyq; and J,
propl .
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R =
Rt2 ' Rtl
wx + w2
Fig. 21. Equation for resolution of two components. R - resolution.
(Rt? - R.,\ - difference in retention time between the two components,
(retention time is measured at peak maximum). ((W, + Wp)/2) - average
of peak widths measured at 10% above the baseline of each peak.
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COLUMN TEMP C
Fiq 22 Effect of column temperature on drug elution.
Mobile
phase flowrate 1.0 ml/min. Components are: A, procainamide;
B, NAPA; C, NPP; D, lidoc; E, NDAD; F, 4-OH propl; G, disop;
H, quin: I, dihyq; and J, propl.
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COLUMN TEMP UC
Fig. 23. Effect of column temperature on drug elution. Mobile
phase flowrate 0.5 ml/min. Components are: A, procainamide;
B, NAPA; C, NPP;-D, lidoc; E, NDAD; F, 4-OH propl; G, disop;
H, quin; I, dihyq; and J, propl.
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and 35 C was considered especially important. The instrument is not
capable of oven cooling, and when it is operated at ambient temperature
the column oven is usually three degrees higher, due to heat generated
by the instrument. However, the data indicate that changes in ambient
temperature should not cause elution problems.
At temperatures over 35 C, drug retention time decreases and resol
ution worsens. At 55 C disopyramide and quinidine converge, as do NDAD,
lidocaine, and 4-OH propranolol. Increasing the temperature beyond 35 C
offers no advantage because of poor resolution. Ambient temperature
was chosen for use in the assay.
Isocratic Elution
Isocratic elutions are generally reproducible and more readily
useful for routine analysis. Therefore, all drugs were chromatographed
in mobile phases of fixed composition to determine elution characteris
tics. All assay drugs were run at the following mobile phase ratios of
organic: phosphate: 70:30, 60:40, 50:50, 40:60, and 30:70. The normal
run time of 25 min was increased to 30 min to permit elution of as many
drugs as possible from the column.
Isocratic elution at 30 - 40% organic modifier results in extreme
tailing of the later eluting drugs and in poor separation of the earlier
eluting components. Some drugs do not elute at all. Resolution of N-
propionyl procainamide and propranolol, as determined by using the equa
tion in Figure 21, is 1.59 at 40% organic. By comparison, the gradient
elution program chosen for the assay protocol yields a R of 3.09 for
the same two drugs. The retention times of these two drugs are approx
imately the same in both run. This illustrates the poor resolution and
efficiency of the 40% isocratic run.
At 60 - 70% organic phase the peaks converge and have poor resolution
(Figure 24). Interferences may coelute with the assay drugs, all of
which elute within the first seven minutes.
An isocratic run with 50% organic modifier would be effective for
the analysis of the antiarrhythmic drugs other than procainamide and
NAPA. The remaining drugs separate well and have good peak symmetry.
Isocratic analysis is, however, not appropriate for the simultaneous
assay of all antiarrhythmics in this study. A gradient system was
therefore investigated.
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oc
30 40 50
PERCENT ORGANIC IN MOBILE PHASE
Fig 24 Drug elution using isocratic analysis. Elution of assay components
using mobile phase of fixed organic/phosphate
composition throughout the run.
A dashed line indicates that the component did not elute from the chromatograph
at the indicated isocratic condition. Components are: A, procainamide; B,
NAPA; C, NPP; D, NDAD; E, 4-OH propl; F, disop; G, quin; H, dihyq; I, propl.
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Gradient Development
Several gradient programs were investigated to determine the best
conditions for separation of all components in the assay. This was done
by making adjustments in the length of time during which the mobile
phase composition would change (i.e. the "slope" of the gradient), and
by changing the organic/phosphate ratio at the beginning and end of the
run.
In all runs, the mobile phase composition is constant for the
initial 2 min. At 2 min the linear gradient, described below, begins.
The gradient reaches a final mobile phase composition at the times shown
and this composition is maintained until 25.5 min. The mobile phase
then returns to its initial proportion to equilibrate the column for
5 min before the next run is initiated. The slope of the gradient is
defined as the change in percent organic divided by the time, in minutes,
during which the change takes place.
Experimental Linear Gradients
Gradient Initial %
Organic
Final %
Organic
Grad ient Termination Slope
% org/mi
A 20 70 20 min 2.78
B 20 70 15 min 3.85
C 20 80 20 min 3.33
D 20 70 23 min 2.38
E 30 70 20 min 2.22
F 30 70 23 min 1.90
The slope of the gradient and initial percent organic are cri
tical for adequate separation of all drugs. Steep slopes, such as
3.85% org/mi n in gradient B, do not resolve disopyramide and quinidine.
Gradients using a higher initial percent organic, 30% in gradient E
and gradient F, fail to adequately separate procainamide and NAPA.
Gradients with intermediate slopes, using a 20% organic such as 2.78%
org/min (gradient A), 3.33% org/min (gradient C), and 2.83% org/min
(gradient D) provide the best resolution. Except for lidocaine and
NDAD, all drugs are separated by at least 1.0 min. Gradient A resolved
lidocaine and NDAD better than either gradients C or D'and was therefore
adopted as the gradient of choice. Gradients are presented in Figures
25-30.
METHOD OPTIMIZATION
After the mobile phase conditions had been decided upon, refinements
67
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Fig. 25. Gradient elution. Change in percent organic of the mobile phase
with time, during the run. Gradient A: initial % organic 20., final % organic
70, gradient termination 20 min, slope 2.78 % organic/min. Components are:
A, procainamide; B, NAPA; C, NPP; D, lidoc; E, NDAD; F, 4-OH propl; G,
disop; H, quin; I, dihyq; and J, propl.
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Fig. 26. Gradient elution. Change in percent organic of the mobile phase
with time, during the run. Gradient B: Initial % organic 20, final %
organic 70, gradient termination 15 min, slope 3.85 % org/min. Components
are: A, procainamide; B, NAPA; C, NPP; D, lidoc and E, NDAD (coeluting) ;
F, 4-0H propl; G, disop; H, quin; I, dihyq; and J, propl.
69
00
CQ
o
o
o
<c
C3
OC
o
~ Z"" "
H . ili- !H
- -
-
- - - ,. ..
-.:.:. -zz 'I
. : i. .
'
'.
:' fXiif T -.EEff "XTfi -
: ') Z
rf ZZAA: .1 ..zzz:. ""T-XEf E41T Z.Z- '-.-.
.in! 1.
: nipr E . !. 1
:""::.
-
EE:EX
zzzzrEii ii-riii-H "-^xHii . EEEf i.li
- '
\ZTZ~.
"
-te""
E.
E;'
7 .--.. -zz.i.z :
i
-..-- TEE ii iiEfE
- j -_ ~zzz. li. ! - -A Ifff
1
"'XX
. .
XXL'AzAo T.XX7 iiii ZZZ. 1
CO iEiH
1 f. -:-":E
HiiiHi in iii ZZZZZ nii!
ihTTXT iii
ixx_ .:: - a X"_L , E; XX. ZZ Z f. .
lidE 1
TEXX.pE'X"
XfX-Tff. riLiii
" ZZ"'
.
-
i zz\ ...zzz.
-.ztz-zzz / . xT. E'Ti|:-i- iii. ! !!ii
eX- AAzAZZ
~.zzHE! 1 1 nXilr^.- _ ;
XL..1
1- 1 ""7- iii ~n.i p-_
xJe
'
- - Tr iii Z.ZETeX
.. .
::.
:
1 - - -
irtji iii!zzz ex:ei"ii<-. t: "Hi dC _ 1
r^. |^eXe . " " 4 - ;E - -f '"- ZZZ. E"-E e "Ei -Eip.7 Hii\y A - -i- H .;_4r. i - - - - 1
EffiifT" ...1 -.- -
:-ii EEiETE
1 \ZZ^
,
-zzzAzzL
Hii A
l_n/i
- - - \-/
4Vx -HE-.H.H1
'
"- Z
"
iill-i|
.: 1
ETEi iZZAZz EE:
_
fffi[HfL
tAzzz-i"-X-EifE1 + -Z.AzL.AZ-.
r.
E-E--E
in. , T-ii
V> Hiiliiii
.iiiix i_4- -.. EEi
j. __ .,. ...
~zzzzzz-7
1
X
- t
iij ii
i...r
hx
. .-i- .. + . _ -Ay . Hiiii
1
i.XiH! j EipiEq : iiphinEETET ". -zAfizZZzL TXXE. liiHlii
i.ipi-
:TX-TX Ef
1
-
XXH..HH
[--
-i
4 i-rE-1 i. X "-XEXffill /--A XX
J^
iXqfi- --!E!liiEXX: if TE - i
HiX-i:i. H!J! et-:x-~
"
z-/.z
1 EEEfTXr+TXpi-T A :j EhhThEtET.XXmi 1
.- v-o:;.-1. ..
ET-EEi -XE dC
Z !_ Ja -eE"ET ...Hrni.... ...
1
niiinrf-i
Ei-
ii -tEi-
XiiX
1 ;--
-
Hilil f --'-/X_'-rE
d
1
,
:Xi...
- ! - 1
i
h: -innr , 1 Hiii'lil
11.--
_. |
'
r 1 1 .
ZZZZZZZZ-ZZZZZr.X
-
hi: :.-.-.:... / iifnE - : ..... - Xr " "1
z ::
- zzz- - 0 . -- / X jrn-EL- " nxW-idrn EXT E Ef EX . i tI
o
"3"
...... . f . . - -.
_:_-.:
- EEE iii 1 ZAgzzff. .. i. E fXEETE ii
1 :.-_
Ei-"
ZZ.Z.
.. j. .. .
1
. ; - -i
- -
.
-:'.:--"-"- -
.ZZ.H_
ii
. .
-^
. .
EE-piET-k.-E ETT^zzzzz/Z iEHLiiZZZV""-rrr ErrE .. Ei!E-|- THi E El -.1
--I
:.:
I. ...
. ..."\ZZZZ
AZ-Zz'A-
iff
"-EEE XfEiTTi Eiir zzzzrzzzz ZZ-Axx
. ..
1
_......
E.EXET 1
zzzz -J\
'4~
1
J--
rnn:i r "EX EIE ""E.
-E.-pE
in--
-f EEE
- j
/. \~-ZZAZZ~Z X .. . iiii
o
EfEX / Liij
HHH-I ip -E
"
- Iii!CO - i
i
..
....H .-,
-_ _ H- zzzz.d~E
~ T""" ' '
-4
ZzA-AZZ
T_ 1X]f"f Ey t
i
!li-iil
- - i j
-X-.-.; - A
...-.
1 1 , - -ri
'
-
1
i . . . .
1- ("
1
EEi- -r-H, i|
i
H-HHVf|X= ...
_-
iiniii
rf
,
......
"
'
... 1
.ZZZZZIZ-ZZZ
-
IE! i. :nr
i_-
.-iii
: --1
_:
CM ~t~ 1
i
.
;
-
r
- d-
EH
1 H
-t- - -
1. . . 4 1
XTX.4:EETE
zzzzz. .
zzzzzz
=
xH
E XEEiXTEX
zzz -_
... 1
1
.ii-d
- -
-
llir_l_
r i-PHi
. - -
_!
XfXftfXTE
[ZZZZ[ f.EI
o
r-H
zz.zz1'..:-
-
F=F
1
1
.
1'
1
-
-
HHjH_i
"
"z-
:
-i~
E
.. _+
.....
I "*
. EEXf . ..._.Z\
1
1
.. . . L.
EifcnE
zzzzzzzzzzz
1
l"i-Hp_i -X :
- - ' -
^
zzz -
-
-
-e-;
'
. , ,
EXXE
J^
lE!riiLnEi4-
i-iE
t
rTxE4"'!:fE-
-. -.
ZZZ."J. !_ -- End T - E' - ~-y r
12
TIME MIN.
16 20 24
Fig. 27. Gradient elution. Change in percent organic of the mobile phase
with time, during the run. Gradient C: Initial % organic 20, final %
organic 80, gradient termination 20 min, slope 3.33 % org/min. Components
are: A, procainamide; B, NAPA; C, NPP; D, lidoc and E, NDAD (coeluting);
F, 4-OH propl; G, disop; H, quin; I, dihyq; and J, propl.
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Fig. 28. Gradient elution. Change in percent organic of the mobile phase
with time, during the run. Gradient D: Initial % organic 20, final %
organic 70, gradient termination 23 min, slope 2.38 % organic/mm. Components
are: A, procainamide; B, NAPA; C, NPP; D, lidoc; E, NDAD; F, 4-OH propl;
G, disop; H, quin; I, dihyq; and J, propl.
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Fig. 29. Gradient elution. Change in percent organic of the mobile phase
with time, during the run. Gradient E: Initial % organic 30, final % organic
70, gradient termination 20 min, slope 2.22 % org/min. Components are:
A, procainamide; B, NAPA; C, NPP; D, lidoc and E, NDAD (coeluting); F, 4-OH
propl; G, disop; H, quin; I, dihyq; and J, propl.
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Fig. 30. Gradient elution. Change in percent organic of the mobile phase
with time, during the run. Gradient F: Initial % organic 30, final %
organic 70, gradient termination 23 min, slope 1.90 % org/min. Components
are: A, procainamide; B, NAPA; C, NPP; D, NDAD; E, lidoc; F, 4-OH propl;
G, disop; H. quin; I, dihyq; and J, propl.
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were made in the instrument settings to select a detector wavelength
where propranolols absorption would be maximum. This was necessary
because of the drug's low therapeutic serum level, (20 - 100 yg/ml ) .
Ultraviolet absorption scans were performed. The necessary specimen
and injection volumes to be used in the assay were also determined with
the propranolol sensitivity requirements in mind.
Wavelength For Analysis
All drugs were prepared in mobile phase at a concentration of 5.0
mg/L. Each was then scanned in a Perkin-Elmer 559 UV/VIS spectropho
tometer from 500 nm to 190 nm. The liquid chromatograph is also capable
of scanning but the time required is considerably longer than with the
Perkin-Elmer. A liquid chromatographic scan of propranolol (Figure 31)
is included for illustrative purposes.
The wavelength for analysis was chosen at propranolol's absorbance
maximum of 212 nm. All other drugs have sufficient absorbance at this
wavelength to allow accurate quantitation. A reference wavelength of
430 nm was selected because none of the drugs absorb at this wavelength.
The data in Table 20 point out the advantage of a variable wavelength
detector. Propranolol and lidocaine have over a 20 fold increase in
absorptivity at 212 nm when compared to 254 nm. Seven of the other
components have at least a two fold increase in absorptivity at the
lower wavelength.
Assay Volumes
The assay volumes were selected to maximize the peak area of pro
pranolol and thereby enhance its analytical sensitivity. The volume
of mobile phase used for reconstitution after extraction was 150 yl .
An injection volume of 75 yl was used. This volume allowed 50% of
all extracted material to be injected into the chromatograph. This per
centage is the maximum possible amount with the available vials and in
jection system.
The Clin-Elute CE-1003 column can handle a maximum of 3.0 ml of
aqueous material without overloading the column matrix (19). By using
2.5 ml of serum and 200 yl of Na2C03 in the extraction procedure,
2.7 ml of aqueous material is placed onto the column. The volumes
selected for use in the assay protocol maximize the amount of drug
injected into the chromatograph. This should allow quantitation of
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SCHN ULMftX 54B START SPL
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Fig. 31. HPLC ultraviolet absorbance scan of propranolol from 190 nm
to 540 nm. Absorbance readings are taked every 2 nm. Wavelength (nm)
is printed every 50 nm.
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TABLE 20. ULTRAVIOLET ABSORBANCE SCANS AT SEVERAL WAVELENGTHS
Absorbance
Drugb 205 nm 210 nm 212 nm 220 nm 254 nm
Procainamide .55 .46 .45 .27 .23
NAPA .61 .47 .40 .25 .35
NPP .54 .44 .37 .26 .30
NDAD .43 .32 .28 .20 .09
Disopyramide .45 .32 .28 .16 .07
Quinidine .74 .68 .61 .50 .35
Dihydroquinidine .61 .56 .52 .41 .23
Propranolol .75 .88 .88 .75 .04
Lidocaine >1\0 >1.0 >1.0 .60 .05
a
Instrument sensitivity 1.0 AUFS.
b Concentration (5 mg/L) in mobile phase.
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propranolol in the therapeutic range of 20 - 100 yg/L.
Internal Standard Selection
Procaine, P-chlorodisopyramide, and N-propionyl procainamide were
evaluated as suitable internal standards in the assay. Procaine was
rejected as an internal standard because of its tendency to "tail"
under the chromatographic conditions of the assay. P-chlorodiso
pyramide was also rejected. It eluted very late into the run (20 min)
and had only a 74% extraction efficiency. It was also
found to coelute with carbamazepine and potentially interfere with
accurate quantification of propranolol (see Interference Study Table 9).
N-propionylprocainamide proved to be a suitable internal standard.
It elutes about midway into the run and has an 84% extraction efficiency.
None of the forty- two drugs tested in the interference study elute
within 2 min of NPP. NPP was adopted as the internal standard for the
assay protocol .
The amount of N-propionylprocainamide was selected in order to
produce a peak area ratio of drug (or metabol ite)/internal standard
as near to unity as possible when the drug is in the therapeutic range.
The variation of absorptivities at 212 nm, and the expected amount of
material extracted from serum for each analyte, produced a large range
in the ratios. The area ratio at the mean concentration of the run-
to-run precision study is shown in Table 6. Even at the small peak
area ratio for propranolol, the microprocessor is able to compute the
area precisely enough to achieve a relative standard deviation of 5.1%.
DRUG EXTRACTION
Several organic solvents were tested for their ability to extract
the drugs of interest from serum. Once extracted, the chromatographic
conditions developed previously were used to quantify the drugs. In
the first experiment, drugs were isolated from serum by manual liquid-
liquid extraction. In the second part of the study, the drugs were
extracted with the use of the Clin-Elute CE-1003 columns.
Manual Extraction
A control of all antiarrhythmic drugs, at their therapeutic con
centrations was prepared by spiking pooled serum that was known to be
drug free. The control was added to test tubes, followed by 1.0 mol/L
Na2C03 and the appropriate organic solvent. The Na2C03 is necessary
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to adjust the serum to a high pH (approximately 10) where the basic
drugs, existing in an unionized hydrophobic form, can be easily extracted
into the nonpolar solvent. The tubes were vortexed and centrifuged.
The organic layer was then transferred to a new test tube to evaporate
the organic solvent. Each residue was reconstituted with 150 yl of
mobile phase, vortexed, and removed to a microvial for chromatographic
analysis. Solvents of various polarities were selected to test the
drugs extractions (acetonitrile, chloroform, methylene chloride, hexane,
heptane, N-butyl chloride, ethyl acetate, isopropanol, and toluene).
Each of these were also tested with the addition of 2% isoamyl alcohol.
Manual extraction proved to be a poor technique for the isolation
of the drugs from serum. Some extraction tubes formed emulsions.
Others produced a white turbid solution upon addition of the mobile
phase. Long periods of time (30 min) were also required for eva
poration of the extraction solvents. No useful information was gained
from the manual extraction experiment.
Clin-Elute Extraction
Two types of Clin-Elute extractions were performed. The first
employed only a single extraction step. The second utilized an acid
back-extraction to transfer the basic drugs from the organic phase into
a microvolume of aqueous HC1 .
Single Extraction
Clin-Elute CE-1003 columns were prepared by adding 200 yl of 1.0
mol/L Na2C03 and 50 yl of 0.2 mg/L N-propionylprocainamide to each
column. Frozen serum controls of the antiarrhythmic drugs were thawed
and 2.5 ml were then applied to appropriately labeled columns placed
over 16x150 mm test tubes. Three additions of 4 ml of organic solvent
were added to the columns. Each eluted solvent was evaporated to dryness
at 50C. The residues were redissolved in 150 yl of mobile phase and
75 yl of this solution was to be injected into the chromatograph. The sol
vents tested were acetonitrile, chloloform, methylene chloride, hex
ane, heptane, N-butylchloride, ethyl acetate, isopropanol, and toluene.
Each of these solvents was also tested with the addition of 2% isoamyl
alcohol v/v to reduce nonspecific adsorption to glass (20).
Isopropanol and acetonitrile (with of without isoamyl alcohol)
would not pass through the column. The mobile phase reconstitution of
the residues from the other solvent extractions produced milky suspensions.
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To prevent possible damage to the system, the suspensions were not
injected. Neutral extracting serum components may have been responsible
for the suspensions. No useful extraction information was gained in
this experiment.
Dual Extraction
Clin-Elute CE-1003 columns were prepared for extraction of basic
drugs by the addition of 200 yl of 1.0 mol/L Na2C03 and 50 yl of 0.2
mg/L N-propionylprocainamide to each column. The eluent tube placed
under each column had 200 yl of 0.1 N HC1 added to it. Frozen controls
of antiarrhythmic drug in serum were thawed and 2.5 ml were applied to
appropriately labeled Clin-Elute columns. Three addtions of 4 ml of
organic solvent were then added to each column. The eluent tubes were
each vortexed for 45 s to back-extract the basic drugs into the HC1 .
Each tube was centrifuged for 10 min, the organic layer was aspirated
and discarded, and the aqueous HC1 phase was dried under N?, after 300
yl of methanol had been added. The residue in each tube was then re
constituted with 150 yl of mobile phase and 75 yl of this solution
was injected into the chromatograph. The solvents tested were: meth
ylene chloride, chloroform, ethyl acetate, toluene, hexane, heptane,
N-butylchloride, methylene chloride:isopropanol (90:10), and methylene
chloride: hexane (50:50). All of the above solvents and mixtures were
also tested with the addition of 2% isoamyl alcohol.
Residues from methylene chloride:isopropanol extractions formed
slightly cloudy suspensions upon addition of mobile phase. All other
extractions were clear and colorless.
Solvents and mixtures which had densities less than the 0.1 N HC1
were easy to work with because the HC1 would remain as an easily dis
cernible phase at the bottom of the test tube thus making aspiration
of the organic a simple procedure. Solvents that were more dense than
0.1 N HC1 proved to be undesirable because the HC1 remained on top of
the organic phase which made aspiration difficult. It was not possible
to aspirate the organic phase from extractions that had solvent densi
ties near 1.00 gm/cc because no separation of phases occurred after
centrifugation (e.g. methylene chloride:hexane). Solvents with den
sities of less than 0.99 gm/cc should be used to avoid these aspiration
problems.
As shown in Table 21, the more polar drugs, such as procainamide
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TABLE 21. CLIN-ELUTE EXTRACTION EFFICIENCIES. PERCENT RECOVERY OF
ASSAY DRUGS USING THE ESTABLISHED DXTRACTION PROTOCOL WITH
VARIOUS ORGANIC SOLVENTS.
Solvent PA NAPA NPP NDAD DISOP QUIN DIHYQ PROPL
Ethyl acetate 112 117 98 109 105 102 114 26
Ethyl acetate:
IAAa
113 119 97 105 107 104 114 16
Toluene 8 <1 2 1 66 90 74 115
Toluene; IAA 53 18 50 84 106 106 112 100
Hexane <1 <1 <1 <1 <1 <1 <1 62
Hexane: IAA <1 <1 <1 <1 88 104 109 108
Heptane <1 <1 <1 <1 <1 <1 <1 <1
Heptane: IAA <1 <1 <1 <1 86 102 106 107
Butyl chloride 14 <1 5 <1 74 78 67 101
Butyl chlorides IAA 39 1 49 49 90 86 85 76
Methylene chloride: 114
c
112 75 84 18 49 37 <1
Methylene chloride: IPA. IAA 112 104 66 78 16 38 27 <1
Methylene chloride 107 101 92 70 66 91 89 56
Methylene chloride.iIAA 114 113 91 103 56 94 78 22
Chloroform 112 110 94 97 60 90 80 67
Chloroforms IAA 105 107 85 93 44 66 52 19
Methylene chloride;hexane
Assay protocol solvent 96 73 85 102 103 102
105 70
a
b
c
d
e
IAA-isoamyl alcohol (ratio of solvent: IAA is 98:2).
IPA-isopropyl alcohol (ratio of methylene chloride:IPA is 90:10)
Ratio of methylene chloride:IPA:IAA is 88:10:2)
Not assayed because phase separation did
not occur.
Methylene chloride:hexane:IAA 49:49:2.
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and NAPA, extract well into the slightly nonpolar solvents, such as
chloroform. Nonpolar drugs, like propranolol, extract best into very
nonpolar solvents, such as toluene or hexane. The solvent system adop
ted, methylene chloride:hexane:isoamyl alcohol (49:49:2), takes advan
tage of the good recovery of propranolol by hexane- isoamyl alcohol and
the good recovery of the other drugs by methylene chloride. In addition,
the mixture has a density of 0.989 gm/cc, which ensures that the HC1
will remain on the bottom of the tube after centrifugation.
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CONCLUSION
We have developed a high performance liquid chromatographic assay
that is of adequate sensitivity and precision for clinical use. The
extraction and resolution of both drugs and metabolites of a "family"
of pharmacological agents (cardioactive drugs) from spiked sera, allows
the laboratory to use a standard procedure regardless of which drug or
drugs are requested for analysis. The 30 min chromatographic run is
not a major drawback because of the autosampling feature of the chrom
atograph that allows the assay to be performed (after extraction) with
out operator intervention.
The assay has only a limited number of interferences because most
acidic and neutral drugs are removed by the extraction procedure. Al
though carbamazepine and glutethimide may interfere with the quantifi
cation of propranolol, they can be removed by additional organic ex
tractions if the laboratory is made aware of their presence. Quinine
and lidocaine cannot be eliminated as interfering agents by the same
technique due to their basic character. Because it is impossible to
analytically test all drugs and metabolites for interference, we are
closely scrutinizing all patient chromatograms for unidentified peaks.
This specific and accurate liquid chromatographic assay does not
suffer from the many interferences found in manual fluorometric and
colorimetric methods. HPLC compares favorably with enzumeimmunoassay
in its ability to accurately quantitate the drugs of interest. It
also provides a means of monitoring some major metabolites which, with
increased knowledge of drug action, may be clinically useful.
The extensive work performed on the development of the chromato
graphic conditions will be valuable in the implementation of future
assays on this instrument. Several drugs which were tested as inter
ferences are being considered for assay, utilizing the established
chromatographic conditions.
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